A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab

<div>Time course for clinical parameters, diagnosis, and treatment. Nivolumab and ipilimumab were administered at 0, 4, 7, 10, 12, 16, and 18 weeks. CPR: C-peptide reactivity; ACTH: adrenocorticotropic hormone; FT4: free thyroxine; TSH: thyroid-stimulating hormone.</div>

Case Reports in Endocrinology

fig1

Figure 1

Figure 1: A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab 

Figure 1 | A Case in Which HLA-DR4 is Involved in the Development of Complex Immune-Related Endocrinological Adverse Events following Combination Therapy with Nivolumab and Ipilimumab 